• Room 0G.007 - H.S.B

    United Kingdom

19992020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Other

Short Biography

Professor David Gonzalez de Castro was appointed as Professor of Genomic Medicine in May 2016.  His research is centred around molecular biomarker analysis and developing genomic stratification tools for precision medicine with particular focus on developing biomarker strategies for immunotherapeutics and using circulating biomarkers to better classify and monitor disease.  He is involved in several translational research projects identifying diagnostic, predictive and prognostics molecular biomarkers in haematological and solid tumours.  Professor Gonzalez de Castro has been one of the principal investigators on the CRUK stratified medicines programme since 2011, working in close collaboration with clinicians and pharmaceutical and biotechnology industry.  For the last 12 years he has been the Head of the Molecular Diagnostics department at the Royal Marsden and the Institute of Cancer Research in London, where he has been leading the implementation of genomic medicine-driven clinical trials in multiple cancer types, including leukaemias, soft-tissue sarcomas, gastric, colon, lung, skin, prostate, breast and other tumours. He joins CCRCB and the NI-MPL as a Consultant Clinical Scientist, where he aims to further develop genomic stratification protocols to improve patients’ outcomes.

Fingerprint Dive into the research topics where David Gonzalez de Castro is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 28 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

A novel next generation sequencing approach to improve sarcoma diagnosis

McConnell, L., Houghton, O., Stewart, P., Gazdova, J., Srivastava, S., Kim, C., Catherwood, M., Strobl, A., Flanagan, A. M., Oniscu, A., Kroeze, L. I., Groenen, P., Taniere, P., Salto-Tellez, M. & Gonzalez, D., 11 Feb 2020, In : Modern Pathology .

Research output: Contribution to journalArticle

  • Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients

    Sclafani, F., Hulkki Wilson, S., Cunningham, D., Gonzalez De Castro, D., Kalaitzaki, E., Begum, R., Wotherspoon, A., Capdevila, J., Glimelius, B., Roselló, S., Thomas, J., Tait, D., Brown, G., Oates, J. & Chau, I., 14 Jun 2019, In : International Journal of Cancer.

    Research output: Contribution to journalArticle

  • 1 Citation (Scopus)

    A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations

    George, S. L., Izquierdo, E., Campbell, J., Koutroumanidou, E., Proszek, P., Jamal, S., Hughes, D., Yuan, L., Marshall, L. V., Carceller, F., Chisholm, J. C., Vaidya, S., Mandeville, H., Angelini, P., Wasti, A., Bexelius, T., Thway, K., Gatz, S. A., Clarke, M., Al-Lazikani, B. & 17 others, Barone, G., Anderson, J., Tweddle, D. A., Gonzalez, D., Walker, B. A., Barton, J., Depani, S., Eze, J., Ahmed, S. W., Moreno, L., Pearson, A., Shipley, J., Jones, C., Hargrave, D., Jacques, T. S., Hubank, M. & Chesler, L., Nov 2019, In : European journal of cancer (Oxford, England : 1990). 121, p. 224-235 12 p.

    Research output: Contribution to journalArticle

    Open Access
    File
  • 1 Citation (Scopus)
    42 Downloads (Pure)

    Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance

    Pearson, A., Proszek, P. Z., Pascual, J., Fribbens, C., Shamsher, M. K., Kingston, B., O'Leary, B., Herrera-Abreu, M. T., Cutts, R. J., Garcia-Murillas, I., Bye, H., Walker, B. A., Gonzalez De Castro, D., Yuan, L., Jamal, S., Hubank, M., López-Knowles, E., Schuster, E. F., Dowsett, M., Osin, P. & 6 others, Nerurkar, A., Parton, M., Okines, A. F., Johnston, S. R. D., Ring, A. & Turner, N. C., 07 Oct 2019, In : Clinical Cancer Research.

    Research output: Contribution to journalArticle

  • Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

    Hall, A., Buckley, H. L., Flanagan, L., Gonzalez de Castro, D., Farnell, K., Moss, L., Gregory, R., Newbold, K., Du, Y., Flux, G. & Wadsley, J., 14 Jun 2019, In : BMC Cancer. 19, 10 p., 582.

    Research output: Contribution to journalArticle

    Open Access
    File
  • 1 Citation (Scopus)
    97 Downloads (Pure)